Comment from Foley and Lardner LLP

Summary: LNK International, Inc., a generic pharmaceutical manufacturer, opposes the proposed labeling changes for acetaminophen-containing products. They argue that the current warning statement is sufficient, the proposed changes lack scientific evidence, and that implementing them would be burdensome and confusing for consumers and manufacturers.